Related Experiment Video

Updated: Sep 8, 2025

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema
05:44

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema

Published on: January 12, 2017

10.1K

Get It Off Your Chest: A Narrative Review of Breast Ulcers

Eran Shavit, Afsaneh Alavi

    Advances in Skin & Wound Care
    |June 15, 2022
    PubMed
    Abstract

    More Related Videos

    Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis06:03

    Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

    Published on: February 6, 2020

    6.7K
    Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing07:38

    Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

    Published on: September 13, 2016

    8.5K

    Related Concept Videos

    Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

    Peptic Ulcer Disease V: Surgical Management and Nursing Care

    Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
    Surgical Interventions for Peptic Ulcer Disease
    403
    Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

    Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

    Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
    Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
    193
    Peptic Ulcer Disease I: Introduction01:30

    Peptic Ulcer Disease I: Introduction

    Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
    An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
    Peptic ulcers can also be...
    282
    Peptic Ulcer Disease II: Pathophysiology01:28

    Peptic Ulcer Disease II: Pathophysiology

    Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
    Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
    821
    Peptic Ulcer Disease IV: Management01:26

    Peptic Ulcer Disease IV: Management

    Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
    The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
    Pharmacological management
    The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
    144
    Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

    Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

    The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
    Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
    595